

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
12 August 2021 (12.08.2021)



(10) International Publication Number
WO 2021/158413 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) G01N 33/574 (2006.01)
A61K 39/395 (2006.01) A61P 35/04 (2006.01)

(21) International Application Number:

PCT/US2021/015362

(22) International Filing Date:

28 January 2021 (28.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/970,496 05 February 2020 (05.02.2020) US

(71) Applicants: **THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 210 West 7th Street, Austin, TX 78701 (US). **IMMUNE-ONC THERAPEUTICS, INC.** [US/US]; 795 San Antonio Road, Palo Alto, CA 94303 (US).

(72) Inventors: **AN, Zhiqiang**; 6323 Hermann Lake Dr., Houston, TX 77021 (US). **ZHANG, Ningyan**; 6323 Hermann Lake Dr., Houston, TX 77021 (US). **KU, Zhiqiang**; 7900 Cambridge St., Apt. 19-1A, Houston, TX 77054 (US). **ZHANG, Chengcheng**; 1220 Burney Ln., Southlake, TX 76092 (US). **LIU, Xiaoye**; c/o UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390 (US).


CHEN, Heyu; c/o UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390 (US). **XIE, Jingjing**; 2501 Hunters Run, Plano, TX 75025 (US). **COSTA, Maria, Jose**; c/o Immune-Onc Therapeutics, Inc., 795 San Antonio Road, Palo Alto, CA 94303 (US). **SONG, An**; c/o Immune-Onc Therapeutics, Inc., 795 San Antonio Road, Palo Alto, CA 94303 (US). **LIAO, X., Charlene**; c/o Immune-Onc Therapeutics, Inc., 795 San Antonio Road, Palo Alto, CA 94303 (US).

(74) Agent: **HIGHLANDER, Steven, L.**; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Bldg. One, Suite 200, Austin, TX 78746 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

(54) Title: NOVEL LILRB2 ANTIBODIES AND USES THEREOF



(57) Abstract: Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))